Welcome to UK420

Register now to gain access to all of our features. Once registered and logged in, you will be able to contribute to this site by submitting your own content or replying to existing content. You'll be able to customize your profile, receive reputation points as a reward for submitting content, while also communicating with other members via your own private inbox, plus much more!

This message will be removed once you have signed in.

Seedsman Seeds

Support forum for Seedsman Seeds


167 topics in this forum

    • 5 replies
    • 93 replies
    • 10 replies
    • 59 replies
    • 15 replies
    • 53 replies
    • 67 replies
    • 26 replies
    • 99 replies
    • 3 replies
    • 30 replies
    • 5 replies
    • 12 replies
    • 15 replies
    • 0 replies
    • 7 replies
    • 51 replies
    • 4 replies
    • 14 replies
    • 8 replies
    • 0 replies
    • 38 replies
    • 0 replies
    • 2 replies
    • 221 replies

  • Posts

    • Saddam
      Just ignore the hospital related stats on alcohol and tobacco then, it's fine.  
    • MindSoup
      +1 from what I remember of the picture.
    • Joolz
      By Colin Lightfoot, M.Sc. Infection and ImmunityJun 27 2022Reviewed by Benedette Cuffari, M.Sc.   Cannabis is the most widely used psychotropic substance worldwide and is the second most commonly smoked substance after tobacco.   Tobacco use is associated with reduced air flow rate and lung volume; however, this association is not observed with cannabis use. In fact, one 2012 study found no association to exist between occasional and minimal cumulative cannabis usage and poor pulmonary function.   To determine the different effects of cannabis and/or tobacco, it is crucial to know the quantity of how much was smoked. Those who frequently use tobacco will typically smoke between ten and twenty cigarettes each day, whereas the average cannabis user will smoke two to three times per month.   Many people first try cannabis in their late teens or early twenties, with some continuing to use cannabis for several years at modest doses. Since heavy cannabis users were comparatively uncommon in the study population, accurate estimates of the consequences of excessive usage were not available in the aforementioned 2012 study, despite the fact that heavy exposure to cannabis may harm the lungs.   In a recent Chronic Diseases and Translational Medicine study, researchers evaluated the effects of smoking cannabis on coronavirus disease 2019 (COVID-19) test positivity, as well as potential risk factors associated with cannabis-induced lung damage and COVID-19. About the study Approximately 500,000 men and women participated in the United Kingdom Biobank (UKB), which is a sizable prospective observational study that was conducted between 2006 and 2010. UKB participants were selected from 22 centers throughout England, Wales, and Scotland and are still being longitudinally monitored to record any subsequent health occurrences.   Study participants were asked several questions upon their enrolment in the UKB. For example, participants were asked whether a doctor had ever informed them that they have a certain health condition, such as chronic obstructive pulmonary disease (COPD).     The subjects were then asked whether they had consumed cannabis. If the response was "yes," cannabis usage was entered in the UKB data field. The participants were also asked at what age they had last consumed cannabis.   Subsequently, study participants were asked the frequency to which they used cannabis. The available response options included less than once a month, once a month or more, but not every week, once a week or more, but not every day, and once a day.   The researchers also incorporated COVID-19 laboratory-confirmed cases that were reported between March 16, 2020, to April 26, 2020, with the UKB data. A positive test result was regarded as a reliable indicator of severe COVID-19 during this time, as the testing of older groups was primarily restricted to individuals who were hospitalized as a result of their infection. Study findings The mean age of the study participants was about 57 years old. Taken together, 54% of the study participants were women, whereas the remaining 46% were men. Increased cannabis use was associated with an increased incidence of both COPD and COVID-19 positivity. Packs-years smoking was also found to correlate with COVID-19 incidence. Implications In general, smoking tobacco increases an individual’s risk of lung infections like COVID-19. Although the data is limited in establishing an association between the smoking of cannabis and its effects on the lungs, previous research has shown that cannabis smoke causes respiratory symptoms such as increased cough, sputum, and hyperinflation, all of which are also observed in tobacco smokers.   In the current study, both smoking packs of cigarettes and cannabis had significant effects on the likelihood of testing positive for COVID-19. This observation insinuates that although cannabis had not been used for at least ten years, its ability to cause damage to the lungs is additive.   Although it is challenging to correctly predict and separate the consequences of cannabis usage from those associated with smoking cigarettes, smoking cannabis can nevertheless cause significant harm to the lungs. With prolonged cannabis use, significant lung problems can develop, such as chronic bronchitis symptoms. Cannabis use has also been linked to weakened immune systems and pneumonia.   Excessive cannabis use can also worsen COVID-19 outcomes and restrict the airways. However, cannabis use may reduce lung inflammation and inhibit viral replication in COVID-19 patients, which may improve certain prognoses. Study limitations There are several notable weaknesses of the current study. For example, cannabis usage was only linked to positive COVID-19 test results. Furthermore, the frequency of cannabis usage and its ability to alter an individual’s susceptibility to COVID-19 was not explored. The high prevalence of Caucasian participants may have also impacted the current findings. Future studies that incorporate more independent variables in the logistic regression would be beneficial. Journal reference: Lehrer, S., & Rheinstein, P. H. (2022). Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection. Chronic Diseases and Translational Medicine. doi:10.1002/cdt3.38.     https://www.news-medical.net/news/20220627/The-impact-of-cannabis-use-on-COPD-and-COVID-19.aspx
    • Joolz
      People who reported using cannabis within the last year had much greater odds of being admitted to hospital or visiting the emergency room than people who did not use the drug, according to a study published Monday in BMJ Open Respiratory Research, suggesting recreational weed might not be as harmless as many think amid an increasing push towards legalization.   Cannabis was linked with a higher risk of being hospitalized or visiting the ER.   Key Facts Cannabis users—the vast majority of whom researchers said would have used the drug recreationally—had a “significantly greater” risk of being admitted to hospital or visiting the emergency room for any reason than people who did not use the drug, according to the peer reviewed analysis of health records from more than 15,000 Canadians.   Overall, cannabis users were 22% more likely to visit the ER or be hospitalized, the researchers found, even when factors like age, gender and other health issues were taken into account.   Acute trauma (15%) was the most common cause of ER visit or hospitalization among cannabis users, followed by respiratory problems (14%) and gastrointestinal issues (13%).   The results point to serious health risks associated with cannabis consumption and suggest rising recreational use around the world “is not benign” and should be curtailed.   What We Don’t Know What was behind the study’s findings. As the study was observational, the researchers stress its findings cannot be used to say cannabis use caused the higher rates of hospitalizations and ER visits. The findings could be explained by factors researchers didn't measure or account for in their analysis, they said. The researchers also said the small sample size of the study meant they could not produce a reliable estimate on the difference in risk for all-cause mortality among cannabis users, though the data available found no significant difference. Further research will be needed to confirm the findings and dig deeper into a possible link between all-cause mortality and respiratory illness, the researchers said. Key Background Despite being banned under federal law, cannabis use is on the rise in the U.S. Nineteen states and Washington, D.C., have legalized recreational cannabis, with several other states, including Oklahoma, looking likely to join them this year. Polling suggests a strong majority of Americans support legalization, though efforts to do so federally have floundered, encouraging the growth of a nascent cannabis tourism industry in states that legalize the substance that’s worth an estimated $17 billion. Some 37 states have legalized cannabis for medical purposes and though there is evidence some cannabis compounds, such as CBD, might be useful in treating issues like chronic pain, a lot remains unknown and the science is far from settled. Many of the purported health benefits from cannabis-derived products are over-hyped or false, lacking solid evidence and extrapolated from clinical trials that differ significantly from how the drug would be used recreationally. The medical hype can obscure the fundamental fact that cannabis is a drug and that there is clear evidence its recreational use can cause harm, particularly among younger people. This includes an increased risk of serious psychiatric disorders like schizophrenia. Big Number $100 billion. That’s how much the cannabis industry in America could be worth in 2030. Legal sales hit an estimated $25 billion in 2021.   https://www.forbes.com/sites/roberthart/2022/06/27/recreational-cannabis-not-as-harmless-as-people-think-study-suggests/?sh=7087a46e5637